That is, when the concentration of transferrin as the major iron transporter protein [6] in the blood of breast cancer patients decreases, the concentration of lipocaline 2 in their blood increases as an alternative mechanism to meet the demand of cancer cells for iron, which cannot be mediated solely via the Tf-TfR-mediated pathway. The gene discussed is TFRC; the disease is breast carcinoma.